Show simple item record

dc.contributor.authorTay, Rebecca
dc.contributor.authorChiramel, Jaseela
dc.contributor.authorMontague, E
dc.contributor.authorWilson, F
dc.contributor.authorSummers, Yvonne J
dc.contributor.authorBlackhall, Fiona H
dc.contributor.authorCalifano, Raffaele
dc.date.accessioned2019-04-29T09:49:02Z
dc.date.available2019-04-29T09:49:02Z
dc.date.issued2018en
dc.identifier.citationTay RY, Chiramel J, Montague E, Wilson F, Summers Y, Blackhall FH, et al. 1462P Impact of blood-based biomarkers on survival outcomes with pembrolizumab in pre-treated advanced non-small cell lung cancer (NSCLC) patients (pts). Ann Oncol. 2018;29(suppl_8):529.en
dc.identifier.doi10.1093/annonc/mdy292.084en
dc.identifier.urihttp://hdl.handle.net/10541/621814
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/annonc/mdy292.084en
dc.titleImpact of blood-based biomarkers on survival outcomes with pembrolizumab in pre-treated advanced non-small cell lung cancer (NSCLC) patients (pts)en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UKen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]
refterms.dateFOA2020-04-20T12:04:16Z


Files in this item

Thumbnail
Name:
561666.pdf
Size:
101.6Kb
Format:
PDF
Description:
From UNPAYWALL

This item appears in the following Collection(s)

Show simple item record